IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Leptin Signaling in Lean and Obese Humans (Leptin signali)
This study has been withdrawn prior to enrollment.
(funding expired)
Sponsor:
VA Office of Research and Development
Information provided by (Responsible Party):
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT01297426
First received: February 14, 2011
Last updated: December 23, 2015
Last verified: December 2015
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Obesity does not respond to high circulating levels of the hormone leptin. This study is aiming at finding out why this happens and open new avenues for treatment of obesity.
| Condition |
|---|
| Obesity |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
| Official Title: | Leptin Signaling in Humans |
Further study details as provided by VA Office of Research and Development:
Primary Outcome Measures:
- Westerns / activation of signaling pathways (uo to two hours after treatment) [ Time Frame: 04/01/2016 ]
| Enrollment: | 0 |
| Study Start Date: | April 2011 |
| Study Completion Date: | June 2015 |
| Primary Completion Date: | June 2015 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Group 1
Lean and obese, diabetic and non diabetics
|
Detailed Description:
Ex vivo and in vitro identification and study of leptin signaling pathways in commercially available cell lines serum/ plasma samples and discarded tissues from humans.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
diabetic or nondiabetic lean and obese subjects
Criteria
Inclusion Criteria:
- men and women
- ages 18 to 65
- BMI ranges between 20 and 45 kg/m2
Exclusion Criteria:
- subjects requiring special diets
- history of illness other than obesity of diabetes
- taking medications known to influence glucose metabolism
- subjects with history of anaphylactic reaction or hypersensitivity to e. coli derived proteins or anesthetic agents
- women who are breastfeeding, pregnant or wanting to become pregnant
- subjects with bleeding dyscrasia or poor wound healing
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01297426
Please refer to this study by its ClinicalTrials.gov identifier: NCT01297426
Locations
| United States, Massachusetts | |
| VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA | |
| Boston, Massachusetts, United States, 02130 | |
Sponsors and Collaborators
VA Office of Research and Development
Investigators
| Principal Investigator: | Christos Mantzoros, MD DSc | VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA |
More Information
| Responsible Party: | VA Office of Research and Development |
| ClinicalTrials.gov Identifier: | NCT01297426 History of Changes |
| Other Study ID Numbers: |
ENDA-013-10F |
| Study First Received: | February 14, 2011 |
| Last Updated: | December 23, 2015 |
ClinicalTrials.gov processed this record on September 21, 2017